Actively Recruiting
A Phase 3 Study Comparing BL-M14D1 Plus Atezolizumab With Standard Therapy in Adults With First-Line Extensive-Stage Small Cell Lung Cancer
Led by SystImmune Inc. · Updated on 2026-10-15
550
Participants Needed
62
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a new drug combination, BL-M14D1 with atezolizumab, compared to the current standard treatment in adults with previously untreated extensive-stage small cell lung cancer ES-SCLC. This global, open-label Phase 3 study compares these therapies to standard care, which includes carboplatin plus etoposide chemotherapy and atezolizumab, sometimes followed by lurbinectedin. Participants receive either BL-M14D1 and atezolizumab intravenously every 21 days or the standard treatment consisting of carboplatin, etoposide, and atezolizumab for four cycles, followed by maintenance with atezolizumab alone or with lurbinectedin if approved. Treatments continue based on the protocol, and the study is randomized with parallel groups. During the study, participants undergo regular assessments including scans to measure tumor response, lab tests, and evaluations of safety and quality of life for up to five years. The main outcome is progression-free survival measured for up to two years. Researchers will also monitor overall survival, adverse events, and the impact of treatment on participants well-being over time.
CONDITIONS
Brief Title
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Research Team
L
Loren VanPelt
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here